This now completely a JNJ 'game' concerning IMET (pipeline, transitional, remissions, disease altering, combinations, etc.). Now is the time to wait and see as we lead into ASH 2017 (medical journals & conferences).
Janssen Pharmaceutical Companies Selected NME Pharmaceutical Pipeline Selective Highlights as of July 18, 2017
Stocks with share prices under $5 are rarely worth owning. On the rare occasion, however, small-cap healthcare stocks can be glaring exceptions to this general rule.
At the top of my page it says, 11,319 reactions on $GERN conversation. Depending on who you mute it might be different for U.
Then I looked at William's posts and it says 6465 reactions. So 57% of the posts here on my Geron Conversation page are by William.
No judgment here just saying. ;) ;)
9/29/2011 Geron Corporation (Nasdaq: GERN) announced today that its board of directors has appointed John A. Scarlett, M.D. as its Chief Executive Officer. GERN was $1.94. We did not have a deal with Johnson and Johnson or a deal with AST or AST stock. Now we have AST stock and 2 deals with Johnson and Johnson plus GERN is up 45% from when John A. Scarlett became president. GERN is up 45% and the shorts have shorted 33 million GERN shares to keep GERN under $20 a share but the shorts have their back against the wall now because the shorts have to buy all 33 million GERN shares back which will drive GERN's stock price to over $20 a share.
In 2014, as another example, J&J worked out a licensing deal with clinical-stage biotech Geron (NASDAQ: GERN) for its experimental myelofibrosis and myelodysplastic syndromes drug imetelstat. In early-stage studies, imetelstat demonstrated partial and complete responses in some myelofibrosis patients, marking the first time ever in a clinical study targeting myelofibrosis that objective responses were observed. Previous drugs had only worked to diminish symptoms associated with the disease and did nothing for the actual root cause. If approved, imetelstat has blockbuster potential, giving Geron the ability to earn up to $935 million (inclusive of its up-front cash and milestone revenue), as well as sales royalties.
And even more recently, we saw J&J increase its dividend by just 5%, which was the smallest percentage increase this decade. What this likely implies is that J&J does want to take care of its long-term shareholders, but it also wants to keep as much cash flow at the ready to make earnings-accretive acquisitions, should they present themselves.
Here's Why Johnson & Johnson Is Valued at Its Highest P/E in a Decade
Healthcare conglomerate Johnson & Johnson (NYSE: JNJ) is what you might refer to as a "mainstay investment" for a lot of people. It's the largest publicly traded healthcare company in
Blackmarango1 hour ago Been waiting for over 17 years!
Rocky44- Skunko BM...did you mean to say that you've been bashing for 17 years? If you're truly a shareholder, you have a peculiar way of backing up your investment..Go peddle your BS somewhere else Skunkman..
This must be your day off?? Does that mean you'll be posting all day long?? Your posts lately seem to tell me that you've lost interest in your bashing ways..You just come in here, spray your Skunk fumes, urinate on this board, and off you go to your lair..
I have an idea for you Skunkman...After one of your morning wretched farts wake you up, go outside and run a little...ride a bike...Take a walk downtown (and do try not to scare the ladies) and breathe some fresh air..You've been a Skunk all your life..try a new smell for a change.
My Take....JNJ would not embaress their reputation by listing a Drug on their Pipeline List of Blockbuster drugs on a WHIM....JMHO
Short-sellers have lost $7.1 billion betting against this year's hottest tech stocks
Tech stock short sellers have been crushed this year
Johnson and Johnson is a $365 billion company and this week Johnson and Johnson has shown the whole world that Johnson and Johnson has put their full support behind GERN. JNJ calls GERN 1 of their top 6 future money makers. Those shorting the 33 million GERN shares better wake up fast because Johnson and Johnson / GERN will destroy them. The shorts have to buy GERN stock back to make money but when GERN's price takes off the shorts will lose the shirts.
Consistent GERN Well ER despite your rantings, GERN consistently fails to take part in biotech sector upmoves. Chippy and his bridge playing underlings should be held fully accountable for failing to attain market recognition.
insipid marango dance your black dance regurgitating your tedious repetitive rants living your life to suck hedgie boot thank baby Jesus I have you on mute.
Breakout day coming
Just last week JNJ was bragging that GERN'S drug was 1 of JNJ top 6 future revenue producers. GERN has 33 million shorted shares that need bought up now.
If the shorts buy back all 34 million shorted GERN shares Monday GERN will close at over $50 a share.
GERN CHART The one year chart shows a gigantic cup and handle, now can you have a one year cup and handle? Cup and handle means the stock is going up. The chart for the last two months shows a wedge which means there is going to be a break out but wedges don't suggest up or down.